FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN) in a report published on Sunday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of FibroGen in a report on Tuesday, March 18th.

FibroGen Price Performance

NASDAQ FGEN opened at $0.31 on Friday. FibroGen has a 12 month low of $0.18 and a 12 month high of $2.40. The firm has a market capitalization of $31.67 million, a PE ratio of -0.26 and a beta of 0.82. The company’s 50 day simple moving average is $0.46 and its 200 day simple moving average is $0.43.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08). The firm had revenue of $3.14 million for the quarter, compared to the consensus estimate of $24.91 million. Sell-side analysts anticipate that FibroGen will post -0.8 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director James A. Schoeneck bought 250,000 shares of FibroGen stock in a transaction dated Thursday, March 20th. The stock was acquired at an average cost of $0.35 per share, with a total value of $87,500.00. Following the completion of the acquisition, the director now directly owns 323,722 shares in the company, valued at approximately $113,302.70. This trade represents a 339.11 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Thane Wettig purchased 145,000 shares of the company’s stock in a transaction that occurred on Monday, March 24th. The stock was bought at an average cost of $0.35 per share, for a total transaction of $50,750.00. Following the purchase, the chief executive officer now directly owns 543,329 shares in the company, valued at $190,165.15. This represents a 36.40 % increase in their position. The disclosure for this purchase can be found here. 1.98% of the stock is currently owned by insiders.

Institutional Investors Weigh In On FibroGen

A number of large investors have recently made changes to their positions in FGEN. Mackenzie Financial Corp grew its position in FibroGen by 416.6% during the 4th quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 441,083 shares in the last quarter. Velan Capital Investment Management LP acquired a new stake in shares of FibroGen in the fourth quarter worth $42,000. Squarepoint Ops LLC purchased a new position in shares of FibroGen during the fourth quarter valued at $205,000. Two Sigma Investments LP raised its position in FibroGen by 19.6% during the fourth quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock valued at $320,000 after buying an additional 98,888 shares during the period. Finally, Two Sigma Advisers LP raised its position in FibroGen by 18.3% during the fourth quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock valued at $465,000 after buying an additional 135,600 shares during the period. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.